Virax Biolabs Group Limited (VRAX) Gamma Exposure (GEX) & Greeks

Gamma exposure (GEX) analysis shows how options positioning creates dealer hedging pressure across strikes. Includes delta, vanna, charm, vomma, and vega exposure by strike price.

Virax Biolabs Group Limited (VRAX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $1.2M, listed on NASDAQ, employing roughly 17 people, carrying a beta of 1.05 to the broader market. Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. Led by James Foster, public since 2022-07-21.

Greeks exposure analysis shows dealer hedging pressure across strike prices for all six Greeks. No recent options activity for VRAX as of 2026-06-01; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.

Learn how gamma exposure is reported and how to read the data →